Insider Transactions Reported | Ironwood Pharmaceuticals(IRWD)saw insider trading activity on 2/12/2025

Ironwood Pharmaceuticals(IRWD) saw insider trading activity on 2/12/2025, there were 5 insider trades during the day.

【History Insider Transaction】

Declare date	Position	Name	Buy/Sell	Quantity	Price per share/USD	Total Amount/USD
2/12/2025	Chief Legal Officer	John Minardo	Sell	38938	1.76	68.53k
2/12/2025	Principal Accounting Officer	Silver Ronald	Sell	12048	1.76	21.2k
2/12/2025	SVP, CMO, Head-Res&Drug	Shetzline Michael	Sell	41269	1.76	72.63k
2/12/2025	Chief Financial Officer	Martini Gregory S.	Sell	12052	1.76	21.21k
2/12/2025	Chief Executive Officer	MCCOURT Thomas A	Sell	139064	1.76	244.75k
11/20/2024	SVP, Chief Business Officer	Davis Andrew	Sell	5360	4.08	21.87k
11/20/2024	SVP, COO and CFO	Emany Sravan Kumar	Sell	11001	4.08	44.88k
8/14/2024	Chief Legal Officer	John Minardo	Sell	9910	4.27	42.32k
8/14/2024	Principal Accounting Officer	Silver Ronald	Sell	3107	4.27	13.27k
6/12/2024	--	McHugh Julie	Sell	22766	6.29	143.2k

[Company Profile]
Ironwood Pharmaceuticals, Inc. was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals, an S&P SmallCap 600 company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. They are pioneers in the development of LINZESS (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).